文献速递临床微生物质量管理与危急值

新型Etest梯度扩散法检测哌拉西林-他唑巴坦对肠杆菌目、铜绿假单胞菌和鲍曼不动杆菌复合体的多中心评价

Multicenter Evaluation of the New Etest Gradient Diffusion Method for Piperacillin-Tazobactam Susceptibility Testing of Enterobacterales, Pseudomonas aeruginosa, and Acinetobacter baumannii Complex.
PubMed 文献 · J Clin Microbiol · 2020-01-28

本研究多中心评估新型哌拉西林-他唑巴坦Etest与微量肉汤稀释法(BMD)的一致性,采用FDA与ISO 20776-2标准及CLSI-FDA、EUCAST折点。共测试977株临床分离株(肠杆菌目775株、铜绿假单胞菌119株、鲍曼不动杆菌复合体83株)。结果显示总体基本一致率较高,但鲍曼不动杆菌复合体分类一致率较低,部分菌种出现极重大误差。

要点

  • 新型P/T Etest与BMD的基本一致率在肠杆菌目为96.4%-96.6%,铜绿假单胞菌为98.3%,鲍曼不动杆菌复合体为91.6%。
  • 应用CLSI-FDA折点时,分类一致率肠杆菌目93.0%、铜绿假单胞菌93.3%、鲍曼不动杆菌复合体89.2%。
  • 应用EUCAST折点时,铜绿假单胞菌出现2株(6.9%)极重大误差和3株(3.3%)重大误差。

核心结论

  • 新型P/T Etest是检测肠杆菌目、铜绿假单胞菌和鲍曼不动杆菌复合体药物敏感性的准确工具,分类误差有限。

研究设计与样本

  • 多中心评估研究,共测试977株临床分离株(肠杆菌目775株、铜绿假单胞菌119株、鲍曼不动杆菌复合体83株),以BMD为参考方法。

主要发现

  • 总体基本一致率:肠杆菌目按FDA标准为96.4%、按ISO 20776-2标准为96.6%;铜绿假单胞菌为98.3%;鲍曼不动杆菌复合体为91.6%。
  • 应用CLSI-FDA折点分类一致率:肠杆菌目93.0%、铜绿假单胞菌93.3%、鲍曼不动杆菌复合体89.2%。
  • 肠杆菌目中发现2株(1.1%)极重大误差(均为肺炎克雷伯菌),无其他重大或极重大误差。
  • 应用EUCAST折点分类一致率:肠杆菌目94.8%、铜绿假单胞菌95.8%;肠杆菌目无极重大误差,发现2株(0.4%)重大误差。
  • 铜绿假单胞菌应用EUCAST折点发现2株(6.9%)极重大误差和3株(3.3%)重大误差,均因Etest MIC与BMD MIC相差1个倍比稀释度所致。

关键数值与推荐

  • 基本一致率(EA)判定依据FDA和ISO 20776-2标准,分类一致率(CA)依据CLSI-FDA和EUCAST折点。
  • 肠杆菌目EA为96.4%(FDA)和96.6%(ISO);铜绿假单胞菌EA为98.3%;鲍曼不动杆菌复合体EA为91.6%。
  • CLSI-FDA折点下CA:肠杆菌目93.0%、铜绿假单胞菌93.3%、鲍曼不动杆菌复合体89.2%。
  • EUCAST折点下CA:肠杆菌目94.8%、铜绿假单胞菌95.8%;鲍曼不动杆菌复合体无折点。
  • 极重大误差:肠杆菌目1.1%(2株肺炎克雷伯菌);铜绿假单胞菌6.9%(2株)。重大误差:肠杆菌目0.4%(2株);铜绿假单胞菌3.3%(3株)。

临床怎么用

  • 新型P/T Etest可用于肠杆菌目、铜绿假单胞菌和鲍曼不动杆菌复合体的药敏检测,但需注意鲍曼不动杆菌复合体分类一致率相对较低。
  • 应用EUCAST折点解读铜绿假单胞菌时,应警惕极重大误差和重大误差的发生,必要时用参考方法确认。
  • 对于肠杆菌目,新型P/T Etest表现良好,极重大误差率低。

局限性

  • 鲍曼不动杆菌复合体未应用EUCAST折点评价,因当时无可用折点。
  • 研究未报告其他可能影响性能的因素,如不同培养基或操作差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Piperacillin-tazobactam (P/T) is a β-lactam-β-lactamase inhibitor combination frequently used in the hospital setting. Etest is a gradient diffusion method that represents an alternative to broth microdilution (BMD) for performing antimicrobial susceptibility testing. We conducted a multicenter evaluation of the performance of the new P/T Etest compared to that of BMD following U.S. Food and Drug Administration (FDA) and International Standards Organization (ISO) standard ISO 20776-2 criteria using Clinical and Laboratory Standards Institute (CLSI)-FDA and European Committee on Antimicrobial Susceptibility Testing (EUCAST) interpretive breakpoints, respectively. A total of 977 isolates (775 Enterobacterales isolates, 119 Pseudomonas aeruginosa isolates, and 83 Acinetobacter baumannii complex isolates) were tested. Overall essential agreement (EA) was 96.4% and 96.6% for Enterobacterales when FDA and ISO 20776-2 criteria, respectively, were followed. EA was 98.3% for P. aeruginosa and 91.6% for the A. baumannii complex when both the FDA and ISO criteria were followed. Applying CLSI-FDA breakpoints, categorical agreement (CA) reached 93.0%, 93.3%, and 89.2% for the Enterobacterales, P. aeruginosa, and the A. baumannii complex, respectively. Two very major errors (VMEs; 1.1%) were found among the Enterobacterales (for 2 Klebsiella pneumoniae isolates). No additional major errors (MEs) or VMEs were found. Applying EUCAST breakpoints, CA was 94.8% and 95.8% for Enterobacterales and P. aeruginosa, respectively (no breakpoints are currently available for the A. baumannii complex). No VMEs were observed among the Enterobacterales, but 2 (0.4%) MEs were found. Among the P. aeruginosa isolates, 2 (6.9%) VMEs and 3 (3.3%) MEs were observed. These errors resulted when P/T Etest MICs were 1 doubling dilution apart from the BMD MICs. In conclusion, the new P/T Etest represents an accurate tool for performing antimicrobial susceptibility testing of Enterobacterales, P. aeruginosa, and A. baumannii complex isolates with limited category errors.

来源:J Clin Microbiol,查看原文。版权归原作者所有。

引用

  1. García-Fernández S, Bala Y, Armstrong T, et al. Multicenter Evaluation of the New Etest Gradient Diffusion Method for Piperacillin-Tazobactam Susceptibility Testing of Enterobacterales, Pseudomonas aeruginosa, and Acinetobacter baumannii Complex. J Clin Microbiol. 2020. PMID: 31597745. doi:10.1128/JCM.01042-19

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。